Loading data for BNR — first visit, this takes a few seconds.
Burning Rock Biotech Limi... (BNR)
NasdaqGM: BNR
· Real-Time Price · USD
10.32
+0.62 (6.39%)
At close: Aug 28, 2026, 2:44 PM
The price, the headline numbers and the latest news, in one place.
Burning Rock Biotech Limited (BNR) Stock Price, Analysis & Data
6.39% (1D)
No data available
| Bid | 6.35 |
| Market Cap | 104.09M |
| Revenue (ttm) | 514.43M |
| Net Income (ttm) | -59.32M |
| 1.38 | |
| -0.83 | |
| n/a | |
| -17.02 | |
| P/B (ttm) | 1.35 |
| P/S (ttm) | 0.20 |
| Earnings Date | n/a |
| Ask | 11.48 |
| Volume | 1,375 |
| Avg. Volume (20D) | 17,861 |
| Open | 10.32 |
| Previous Close | 9.70 |
| Day's Range | 10.32 - 10.32 |
| 52-Week Range | 6.79 - 41.72 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About BNR
Burning Rock Biotech Limited develops and sells cancer therapy selection tests in the People's Republic of China and the United States. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company offers next-generation sequencing (NGS)-based tissue, liquid biopsy cancer therapy selection, and prognosis prediction tests for various cancer types, including lung cancer, ...
Industry Diagnostics & Research
Sector Healthcare
IPO Date Jun 12, 2020
Employees 667
Stock Exchange NasdaqGM
Ticker Symbol BNR
Website https://www.brbiotech.com
Financial Performance
In 2025, Burning Rock Biotech's revenue was 539.57M, an increase of 4.6% compared to the previous year's 515.82M. Earnings were -55.35M, a decrease of -84.03%.
Financial StatementsEarnings Surprise
Burning Rock Biotech has released their quarterly earnings on May 30, 2023:
- Revenue of $107.94M misses estimates by $0, with -18.89% YoY decline.
- EPS of -18.1 misses estimates by -4.20, with 27.60% YoY growth.
